Abstract
Abstract
Introduction
Chronic hepatitis B (CHB) is associated with many serious clinical and social consequences. Despite Egypt being classified as a country of low endemicity, the infection is associated with a 15–25% risk of premature death from liver cancer or end-stage liver disease. The national committee of treatment and control of viral hepatitis has already offered a high-quality service for the diagnosis and treatment of CHB on a free basis. The current study aims to estimate the health care resources utilization and the annual direct medical cost associated with different clinical stages of CHB-related disease in Egypt.
Methodology
The data was retrieved through record review for three months in the General Administration of Hepatitis Viruses Control, Egypt. Then, the data was extrapolated to the population level by multiplying the prevalence in Egypt with a focus on the productive age groups (25–59 years).
Results
The cost and utilization of different health care resources increase with disease progression. The total annual direct medical costs due to CHB in Egypt is 21.3 L.E. Billion (4.7 Int$ billion/year) for the management of estimated 1,420,700 CHB patients. The direct medical costs among the productive age group (25–59 years) constitute more than half of the total cost (57%). The highest disease burden is encountered among (25–29 years) age group; 2.695 L.E. billion (0.59 Int$ billion/year). Despite liver transplantation phase being associated with the highest annual cost/patient, the number of patients in this stage is the lowest. Then, it only constitutes 0.04% of the disease direct medical cost in the country. The chronic hepatitis clinical stage constitutes 57.26% of the disease direct medical cost in Egypt’s working age group.
Conclusion
Strengthening the preventive and control measures is mandatory to alleviate the disease’s direct medical costs. Close monitoring of the chronic hepatitis stage is mandatory to prevent disease progression. Enhancement of vaccination efforts will lower the disease prevalence and its cost. The universal health insurance system which is gradually implemented in Egypt nowadays will be a cornerstone in relieving the economic stresses by allowing more access to high-quality health care services.
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. World Health Organization. Hepatitis B fact sheet. Updated 27 July 2020. Available from: [https://www.who.int/news‐room/factsheets/detail/hepatitis‐b]. Accessed July 2021.
2. Lu J, Xu A, Wang J, Zhang L, Song L, Li R, Zhang S, Zhuang G, Lu M (2013) Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 13:37
3. Alavian S, Hajarizadeh B, Asl M, Kabir A, Lankarani K (2008) Hepatitis B virus infection in Iran: a systematic review. Hepat Mon (4):281–294 Available from: https://sites.kowsarpub.com/hepatmon/articles/70005.html
4. Yeekian C, Pitisuttithum P (2014) Costs of chronic hepatitis B patients in a developing country. J Nurs Educ Pract 4(9):128
5. Zhang S, Ma Q, Liang S, Xiao H, Zhuang G, Zou Y et al (2016) Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepat 23:202–210